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Economic evidence is increasingly being used for informing health policies. However,
the underlining principles of health economic analyses are not always fully understood
by non-health economists, and inappropriate types of analyses, as well as inconsistent
methodologies, may be being used for informing health policy decisions. In addition,
there is a lack of open access information and methodological guidance targeted to
public health professionals, particularly those based in low- and middle-income country
(LMIC) settings. The objective of this review is to provide a comprehensive and accessible
introduction to economic evaluations for public health professionals with a focus on
LMIC settings. We cover the main principles underlining the most common types of full
economic evaluations used in healthcare decision making in the context of priority setting
(namely cost-effectiveness/cost-utility analyses, cost-benefit analyses), and outline their
key features, strengths and weaknesses. It is envisioned that this will help those
conducting such analyses, as well as stakeholders that need to interpret their output,
gain a greater understanding of thesemethods and help them select/distinguish between
the different approaches. In particular, we highlight the need for greater awareness of the
methods used to place a monetary value on the health benefits of interventions, and
the potential for such estimates to be misinterpreted. Specifically, the economic benefits
reported are typically an approximation, summarising the health benefits experienced by
a population monetarily in terms of individual preferences or potential productivity gains,
rather than actual realisable or fiscal monetary benefits to payers or society.
Keywords: economic evaluations, cost-effectiveness (economics), cost-utility analysis, cost-benefit analysis,
cost-effectiveness analyses
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INTRODUCTION
Healthcare demand is continuing to grow; however, the resources
available for healthcare are explicitly limited. Consequently,
ensuring the best value for money spent in healthcare has
been placed high on the agenda for governments worldwide,
with economic considerations gaining an increasingly prominent
role when planning, managing and evaluating health systems
(1). Health economic analyses can be used to assess a health
interventions value for money and can support the optimal
allocation of the limited resources available for healthcare (2).
Using health economic analyses to investigate the value for
money of different health interventions is particularly appealing
to decision-makers when considering the use of a public budget
to fund healthcare services. The role of health economic analyses
in informing health policy has increased over time (3, 4).
However, the underlining principles of the different types of
health economic analyses are not always fully understood by non-
health economists, and inappropriate types of analyses, as well
as inconsistent methodologies, may be being used for informing
health policy decisions, particularly in low- and middle-income
country (LMIC) settings where this field of research is less well-
established (5). This limits the potential role of these tools in
informing policy decisions to lead to the greatest health gains.
Although information and methodological guidance for these
health economic analyses are available, it is predominantly in
the form of textbooks and training programs, that are typically
available in and focused on high-income country settings, and
tend to be behind a paywall. Although many of the concepts
are universally relevant, there are issues more specific to LMICs
(such as the different types of data available, effectiveness
metrics, and decision rules) and capacity in these settings is
an ongoing challenge (5). Currently, there is a lack of up-to-
date open access accessible literature focusing on a public health
professional audience in LMICs who are playing key roles in
health resource allocation.
This review provides a comprehensive, transparent, and freely
accessible introduction to economic evaluations—intended to
provide a resource for public health professionals, especially
those in LMICs where such resources are typically unavailable.
Specifically, we provide an up-to-date comprehensive
introduction to the main principles underlining the most
common economic evaluation methods used in the context
of informing resource allocation decisions in global health
[namely cost-effectiveness/cost-utility analyses and cost-benefit
analyses (6)] (Table 1), outlining their key features, differences,
advantages and limitations. By doing this we aim to increase
the overall understanding of the key concepts underlining the
different types of economic evaluations commonly used in
the context of priority setting in healthcare, focusing on LMIC
settings. Understanding the key concepts in this context is critical
as it may influence the appropriate use of each approach as well
as how health economic evidence should be interpreted to inform
health policy. It is envisioned that this will help those conducting
such analyses, as well as stakeholders that need to interpret their
output [such as a cost per quality-adjusted life-year (QALY)
gained, cost per disability-adjusted life-year (DALY) averted,




Cost-effectiveness analysis is a form of
comparative economic analysis that evaluates
two or more policy alternatives in terms of their
relative costs and outcomes, where the
outcomes are measured in a single natural unit
(e.g. life-years gained, disease case averted
etc.).
Cost-utility analysis Cost-utility analysis (a specific type of
cost-effectiveness analysis) is a form of
comparative economic analysis that evaluates
two or more policy alternatives in terms of their
relative costs and outcomes, where the
outcomes are expressed by a generic measure
of health status that considers both the effect
on mortality and morbidity (e.g.,
quality-adjusted life-years (QALYs) and
disability-adjusted life-years (DALYs)).
Cost-benefit analysis Cost-benefit analysis is a form of comparative
economic analysis that evaluates two or more
policy alternatives in terms of their relative costs
and outcomes, where both the costs and
outcomes are expressed in monetary terms. In
principle, it should value the interventions
relevant costs and outcomes based on the
preferences of those affected (i.e., the
individuals’ willingness to pay).
Cost-minimisation
analysis
Cost-minimisation analysis is a form of
comparative economic analysis that compares
the costs of two or more policy alternatives




Cost-consequence analysis is a form of
comparative economic analysis that evaluates
two or more policy alternatives in terms of their
relative costs and outcomes, where the
outcomes are not summarised in a single
measure, and multiple outcomes of interest are
reported.
net monetary benefit, return on investment, and benefit-cost
ratio], gain a greater understanding of the approaches and help
them choose/distinguish between the approaches. Note that this
review focuses on the general application of these methodologies
and is not focused on a particular disease area.
DIFFERENCES IN THE MAIN TYPES OF
HEALTH ECONOMIC ANALYSES USED
FOR EVALUATING RESOURCE
ALLOCATION DECISIONS
There are many different approaches used for health economic
analyses. Some types of analysis only examine the costs of
an intervention or a disease (e.g., cost of illness studies)
independently, whereas other types of analysis evaluate
both the costs and consequences of an intervention. It is
vital to understand the different roles of partial and full
economic evaluations.
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Full Economic Evaluations vs. Partial
Evaluations
Full economic evaluations are a specific type of health economic
analysis that explicitly compare the costs (use of resources) and
consequences (effects) of the health intervention(s) in question
to an alternative course of action, known as the comparator
(Figure 1) (7). Full economic evaluations therefore formally
evaluate at least two alternative courses of action, even when only
looking at a single health intervention/policy. The comparator
(also referred to as the counterfactual or baseline scenario) is
typically chosen to reflect common practise or standard of care
in the setting where the economic evaluation is undertaken.
For example, an economic evaluation of introducing the human
papillomavirus vaccine in the UK would use the pre-existing
cervical cancer screening program as the comparator (8). In some
cases, the comparator will be “do-nothing” or a no intervention
scenario, but it is still a formal part of the analysis which
needs to be clearly acknowledged with the relevant costs and
consequences quantified.
In contrast, partial evaluations (also referred to as partial
economic evaluations) are studies that either:
1 Only examine the costs or consequences of an intervention
independently i.e. they do not look at both or relate the costs
to the consequences. For example, a costing study would
evaluate only the costs associated with an intervention (but not
compare these to its consequences).
2 Examine both the costs and consequences of an intervention
but only evaluate a single course of action (a cost-outcome
study). By doing this they are either explicitly or implicitly
ignoring the comparator, which may overlook relevant
costs/consequences and does not allow for comparisons to
relevant alternative policy options for that setting. These
analyses are therefore not a full economic evaluation—which
has to formally compare the costs and consequences of the
interventions in question to a comparator scenario (Figure 1).
Although partial evaluations can provide useful information,
they cannot alone guide decision-making as only knowing an
intervention’s cost or the economic burden of a disease does
not indicate an intervention’s value of money. In the context
of informing healthcare decision making surrounding resource
allocation, it is vital to evaluate both the costs and consequences
of the intervention in question and to compare it to a relevant
alternative course of action/policy option (the comparator). The
importance of accounting for the comparator is highlighted
in Figure 2. In this hypothetical example, a partial evaluation
would find that the benefits of a new treatment (the monetary
value of its health benefits) outweigh its cost, favouring its
use. However, performing a full economic evaluation whereby
the new treatment was compared to the current standard
practise as the comparator, the analysis would find that the
new treatment is less effective and more expensive than
the current standard practise—leading to the opposite policy
recommendation (Figure 2). This highlights that when relevant
alternative policy options (such as the standard of care) are
ignored, analyses can generate misleading conclusions. Note that
there is variation in the literature regarding if partial evaluations
are referred to as an economic evaluation or not (9). Note that at
times studies can be mislabelled. For example, Zarnke et al. (9)
found that studies labelled as cost-benefit analyses (a type of full
economic evaluation) in the healthcare literature were at times
only partial evaluations (Figure 1).
Different Types of Full Economic
Evaluations
There are five main types of full economic evaluations
used to inform and evaluate health interventions (outlined
in Table 1) (6, 10). In this review, we focus on the most
widely used types, i.e. cost-effectiveness/cost-utility analyses,
and cost-benefit analyses (11, 12). There are other types of
full economic evaluations, namely cost-minimisation analysis
and cost-consequence analysis. As these are less commonly
performed, and in the case of cost-minimisation analysis
only appropriate in rare circumstances (11–13), these are not
discussed in more detail within this review.
These different economic evaluations are based on similar
principles. However, while they may first appear to be
interchangeable, they differ in their fundamental methodology
and interpretation. A key difference across the different
types of full economic evaluation is how the outcome is
expressed (Table 1). Cost-benefit analyses express the benefit or
consequence of the health intervention in question in monetary
terms (10, 14). In contrast, cost-effectiveness analyses measure
the health consequences of the health intervention in a single
natural unit (such as life-years gained, cases averted, or cases
detected), and cost-utility analyses (a specific type of cost-
effectiveness analysis) measure the health consequences using a
generic measure of health status that considers the effects on both
mortality andmorbidity (10, 14), such as DALYs andQALYs (15).
There is also variation in how these different analyses consider
the efficiency of resource allocation (Table 2).
Underlying the differences in how the outcome is expressed
for economic evaluations are differences in the economic
foundations. Cost-benefit analysis is traditionally based on a
welfarist approach foundation, where the health outcomes are
judged by the extent of their contribution to overall societal
welfare based on the preferences of the individuals (their
willingness to pay). In contrast, cost-effectiveness/cost-utility
analysis are based on an extra-welfarist approach foundation,
where the objective is traditionally to maximise contributions to
societal health, measured as the sum of individual health status.
An overview of these foundations is provided in Box 1.
A limitation of this review is that it only discusses the
most commonly used types of full economic evaluations.
However, as well as full economic evaluations, there are other
methods/frameworks used in priority setting in global health
that include health economic analysis. For example, budget
impact analysis examines the financial impact of the adoption
and diffusion of an intervention within a particular setting,
considering its affordability (30). Furthermore, multicriteria
decision analysis (MCDA) is also used to assist policymakers in
choosing between options where there are two or more relevant
criteria (29) and can extend economic evaluation methods to
consider other aspects such as acceptability, ethics and equity.
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FIGURE 1 | The difference between full economic evaluations and cost-outcome partial evaluations.
FIGURE 2 | A hypothetical comparison of the difference between a partial evaluation and full economic evaluation.
Ochalek et al. (20) provide a summary of the methods/tools
available for priority setting focusing on LMICs.
COST-BENEFIT ANALYSES
A cost-benefit analysis (also referred to as benefit-cost analysis)
is a comparative analysis of the relative costs and outcomes
of two or more alternative courses of action, where both
the costs of an intervention and its resulting outcomes are
expressed in monetary terms (31). In the past, it has been
referred to by some as the gold standard economic evaluation
approach (31, 32), and it is also used within other public sectors
(17, 31). Cost-benefit analyses can be used to consider the
optimal allocation of resources in its broadest sense because
once the benefits have been converted into monetary terms
then the net economic benefit of different activities can be
compared (including to those outside of the healthcare sector).
It can therefore consider allocative efficiency across different
sectors/across society (Table 2).
Cost-benefit analyses are commonly summarised by
estimating the net benefit of the intervention (the monetised
benefits minus its costs), or by a benefit-cost ratio (the monetised
benefits divided by its costs) (33). However, other outcome
measures can also be used, such as the internal rate of return.
Conventionally, cost-benefit analysis involves summing the
values of the costs and benefits of an intervention based on the
preferences of those affected (34). The theoretical foundation
of cost-benefit analyses for healthcare is based on the welfarist
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TABLE 2 | A summary of how the different types of analyses consider the efficiency of resource allocation and examples of their use.
Cost-effectiveness analyses Cost-utility analyses Cost-benefit analyses
How they consider the efficiency of
resource allocation
Cost-effectiveness analyses using
disease or programme specific
metrics are often only concerned with
how to use healthcare resources in a
way that maximises their output for
the cost. As such they are
considering technical efficiency,
identifying the option that provides
the maximal health care for a given
cost, or delivering a certain service at
a minimal cost.1
Cost-utility analyses can consider the
optimal allocation of healthcare
resources (such as the mix of
interventions) in a way that results in
the maximum health gain for a given
level of expenditure. In this way, it
considers allocative efficiency within
the health sector (i.e., it only deals
with quasi-allocative assessments)
(16).
Cost-benefit analyses can be used to
consider the optimal allocation of
resources in its broadest sense
because once the benefits have been
converted into monetary terms then
the net economic benefit of different
activities can be compared (including
to those outside of the healthcare
sector). It can therefore consider
allocative efficiency across different
sectors/across society.
Examples of when it is useful Useful when a stakeholder is
interested in a particular output metric
and/or when you do not need to
compare the outcome to other
interventions/policy options.
For example, comparing a range of
different malaria interventions when
investigating the cost per
case averted.
Useful for informing health policy
decisions when directly comparing
different health interventions that fall
within the same budget or benefit
package (such as when considering
the optimal allocation of a health care
budget).
For example, deciding if a new
vaccine or treatment should be
adopted within a national health
benefit package.
Useful for cross-sectoral
comparisons, such as looking at if
other government spending should
be reallocated to the healthcare
sector (17, 18). Also useful when
evaluating health policy/interventions
where the health outcome metrics are
not suitable (e.g., prenatal genetic
screening for Down’s syndrome (19)),
and in certain complex intervention
contexts (such as interlinked
packages of care, where maximising
health is not the only objective).
For example, for considering
non-pharmaceutical interventions for
COVID-19 control in terms of both
health and non-health outcomes.
Note that cost-effectiveness analyses can be used to assess allocative efficiency within and potentially beyond the health sector for life-saving interventions when the outcomes are
measured in terms of deaths averted or life-years gained, etc. (16).
BOX 1 | Summary of the welfarist vs. extra-welfarist approaches to resource allocation.
Under the welfarist approach, the efficiency of a health intervention is based solely on the individuals’ perceived value of the welfare that results from it (known as
individual utilities∗ ). In functioning markets, social welfare based on individuals’ preferences can be revealed through the market. However, due to market failures in
health care, individuals’ preferences must be elicited to value the consequences of implementing health care interventions (20, 21). These individual preferences are
reflected by what the individuals are willing to pay (or give up) for the outcomes of the healthcare intervention in question; the higher their willingness to pay, the
more the individuals prefer the consumption of these healthcare goods/services over alternative goods (22, 23). Under this approach, each individual is considered
to be the best judge of their own welfare (23, 24) and social welfare is typically considered to only be a function of these individual preferences. Improvements
in social welfare are judged in terms of a “potential Pareto improvement,” wherein a given change will be a potential Pareto improvement if individuals benefiting
can compensate those made worse off whilst remaining better off (known as the Kaldor–Hicks criterion) (20, 25). However, this criterion is almost always applied
hypothetically (i.e., no compensation actually needs to be paid) and hence some people do inevitably “win” while others “lose” (20). Here, health is often only taken
into account insofar as it enables welfare to be derived from the consumption of healthcare goods/services (24) that is, only based on individual preferences. This
approach is based on several assumptions regarding individuals’ welfare maximising behaviour, including that individuals will make rational choices based on their
preferences for the consumption of different goods, as well as that social welfare is only a function of such individual preferences (26).
The field of economic evaluation in health care has increasingly adopted an alternative framework, known as the extra-welfarist approach. The extra-
welfarist approach was developed to adapt the classical welfare economic approach to the particular characteristics and context of priority setting within the
healthcare sector (27). There are different interpretations of extra-welfarism, but in practise, they almost exclusively focus on the importance of health as the main
outcome of health policies (27). Consequently, it has been described as introducing an important class of extra welfare sources that allows the consideration of
other factors beyond individual utilities/preferences (22, 23, 28). Because under this approach the most important output of health services is considered to be
health outcomes (28), information regarding different health status or health gains can be considered when evaluating interventions (24). Most extra-welfarists would
argue that the “need for health care” and not individual demand, should be the priority for the allocation of resources within the health sector (27) and individuals’
own judgements about their welfare are not necessarily the most important (24, 28). Extra-welfarism is based on the underlying idea that the assumptions regarding
individuals’ welfare maximising behaviour which underpin the welfarist approach, do not necessarily apply to health behaviours and healthcare (26, 29), and it rejects
the exclusive focus on individual preferences when evaluating health interventions, allowing other factors to be considered (23).
These concepts are discussed further in the following papers (22–24).
∗Note that utility in this context is not the same metrics used with cost-utility analysis [such as quality-adjusted life-years (QALYs) and disability-adjusted life-years
(DALYs)].
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approach (Box 1). Conceptually, this is based on three elements
(18). The first is that each individual is the best judge of their
own welfare (or well-being) (18). The second is that measures
of welfare are what is important when measuring health, and
these are based on the utility (or perceived value) individuals’
receive from the consumption of healthcare goods/services (29).
The third is that the preferred policy/intervention is that which
maximises social welfare, that is, the reallocation of resources for
an intervention are justified as long as the net benefits increase
(or the gains can hypothetically fully compensate costs or losses)
(18). The framework does not typically take into account “who”
is benefiting or losing, and no compensation need actually be
paid (Box 1). For functioning markets, social welfare based on
individuals’ preferences can be revealed through the market
(21). However, due to market failures in health care, individuals’
preferences must often be elicited using other methods (20).
In practise, various methods are used to quantify the health
consequences in monetary terms, including willingness to pay
(Box 2) and valuing productivity gains (Box 3). It is debatable
how many analyses fit within these original underpinnings when
being applied to healthcare decision making.
Within cost-benefit analyses, the decision rule for selecting an
optimal intervention is if its net benefit is positive or its benefit-
cost ratio is above one i.e. if its monetised benefits outweigh
its costs, then the intervention is deemed justified in terms of
increasing societal welfare. Importantly, money or cost savings
are not the primary focus (33). Instead, it typically indicates
the trade-offs individuals are willing to make between spending
on the health intervention outcomes (such as improved health)
compared to other goods and services (33)—at least when based
on willingness to pay estimates. Although formally a cost-benefit
analysis should be based on a welfare economic foundation, the
term is often simplified to studies with both costs and outcomes
expressed in a monetary form.
There are other health economic analyses that express
the benefit of a health intervention in monetary terms,
such as return of investment analysis and social return of
investment analysis. When these formally evaluate the costs and
consequences of an intervention compared to a comparator or
counterfactual scenario (i.e., look at two or more alternative
courses of action), they are a full economic evaluation and are
similar to a cost-benefit analysis and have many of the same
advantages/limitations (Boxes 2, 3). However, when these only
formally evaluate the costs and consequences of a single policy
option and do not appropriately account for the comparator
or counterfactual scenario, they are only a partial evaluation
(a cost-outcome study) (Figure 1). Although these are often
referred to as an extension of cost-benefit analysis, these analyses
are less well defined.
Cost-Benefit Analyses: Advantages
More Consistent With How Other Public Interventions
Are Evaluated and Facilitate Cross-Sectoral
Comparisons
The framework used within cost-benefit analyses is more
consistent with how other public interventions/policies (not only
within the health sector) are evaluated, i.e., based on how much
individuals are willing to trade for the benefits (17, 31). Cost-
benefit analyses can therefore be used to consider the optimal
allocation of resources in its broadest sense because once the
benefits have been converted into monetary terms then the net
economic benefit of very different activities can be compared,
including to those outside of the healthcare sector (53). For
example, the “gain” to society from a new health policy can
be compared to investing in transportation infrastructure or
education (53). This facilitates cross-sectoral comparisons and
allows consideration of the allocative efficiency of resources
across different sectors/society (Table 2). In contrast, cost-utility
analyses typically only consider the allocative efficiency of
resources within the healthcare sector (Table 2).
Potential to Value a Wider Range of Benefits
This type of analysis can incorporate benefits and costs that
fall outside of the healthcare sector. This can capture potential
benefits of interventions missed by cost-effectiveness/cost-
utility analyses.
Monetary Output Is Desirable to a Range
of Stakeholders
A monetary output tends to be desirable to both healthcare and
non-healthcare decision-makers (such as those of the ministry
of finance and patient representatives), as well as the public.
Also, by placing ’proxy’ monetary values on all identified impacts
of interest to the stakeholders they can account for multiple
stakeholders’ views of impact simultaneously. This facilitates the
stakeholders’ voice in resource allocation decisions.
Cost-Benefit Analyses: Limitations and
Areas of Debate
Methodological Difficulties Regarding Placing a
Monetary Value on Health Benefits and Variations
Between Studies
There is no consistently agreed-upon gold standard method for
placing a monetary value on the health benefits of interventions.
Consequently, although they have the same monetary outcome,
the approaches used can be highly variable—making it difficult
to compare different studies (51). The different main approaches
and their associated limitations are outlined further inBoxes 2, 3.
A comparative analysis of the cost-benefit analyses of
vaccination found that applying different approaches to monetise
health benefits in cost-benefit analyses can lead to widely varying
outcomes (51). The variation in the approaches taken (and
their quality) is important as there is always going to be a
need to compare different health economic analyses informing
resource allocation. In addition, the variation in approaches
could lead to biases in the results of health economic analyses and
subsequently, the health policies/decision making they inform.
We would argue that the greater the variation between the
different studies the less useful they are for practically informing
resource allocation within global health. Recently, a reference
case for cost-benefit analysis has been developed (33). These
guidelines will hopefully bring much-needed consistency in
this area.
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BOX 2 | Willingness to pay.
The willingness to pay technique is based on the premise that the maximum amount an individual is willing to pay (or sacrifice) for a given commodity is an indicator
of its “value” to them (35). Using the willingness to pay technique in this context could involve estimating what an individual is willing to pay for certain health benefits,
consequently estimating the value of the health benefits of an intervention in monetary terms for that individual. An advantage of this is that it is argued that when an
individual is considering their maximum willingness to pay, they will take account of all the attributes of the service of importance to them, not just the health gains
(35). Willingness to pay estimates are usually derived using either stated or revealed preference methods. Stated preference methods typically use survey questions
to ask respondents about their willingness to pay for an outcome within a hypothetical scenario (33). In contrast, revealed preference methods indirectly infer the
value of nonmarket outcomes (such as health benefits) from observed behaviours or prices for related market goods (33). For example, some individuals accept
extra income for work that is associated with an increased risk of injury or death or spend more money on items that have enhanced safety features (31). When the
extra income received or increased expenditure is compared to the change in the degree of risk associated with a particular activity, it is possible to establish the
individuals’ personal valuations implicit in the observed behaviour (31). An example of a willingness to pay metric is the “value per statistical life” which captures
how much individuals are willing to pay to reduce the risk of death and is used to estimate a monetary value on reductions in mortality. This is often based on
trade-offs individuals are willing to make between fatality risk and wealth. It is important to note that the term is often misunderstood or misinterpreted as the value
the government or the researcher places on saving a life (36), which is a fundamentally different interpretation/a different type of output.
Willingness to pay methods are associated with several limitations in the context of healthcare:
• Willingness to pay estimates are sensitive to the survey methodology and how the questions are phrased (37, 38). In addition, an individual’s willingness to pay is
inevitably correlated to their ability to pay and therefore willingness to pay estimates may be affected by the individuals’ wealth, income and social status (31, 39–41).
Consequently, it has been argued that monetary valuations of health consequences based on willingness to pay methods leads to evaluations intrinsically favouring
interventions against diseases of the wealthy over those of the poor (40, 41). In addition, both stated preference and revealed preference methods have their own
specific limitations:
• Stated preference methods in this context are based on a number of assumptions, including that individuals’ will make rational choices when valuing different
health outcomes (42, 43). However, the choices given within questionnaires are hypothetical and there is little need for a respondent to think carefully about what
they would choose in a real situation, or to report accurately (33). In addition, when individuals respond to these questionnaires (especially those asking about
unfamiliar outcomes, involving small probabilities and long-time horizons), they tend to ‘construct’ their preferences on the spot in response to context-specific
stimuli (42, 44). Responses are therefore vulnerable to psychological biases (42, 44). Furthermore, unlike when buying private goods, where consumers gather
information, compare it to similar goods and actively evaluate their preferences, they may not have all of the information and knowledge necessary to rationally
value different health outcomes.
• Revealed preference methods indirectly estimate individuals’ willingness to pay by inferring the value of a health outcome from observed behaviours or prices for
related market goods. However, individuals may not have perfect knowledge of the risks associated with the observed behaviours in question, and the estimates
may not be representative of the risk preferences of the overall population (45), potentially biassing the willingness to pay estimates. Revealed preference methods
are often used to estimate the value per statistical life metric. However, far fewer studies are conducted in low- and middle-income countries (LMICs), and the
quality varies widely (17). Consequently, value per statistical life estimates often to need to be extrapolated to LMICs settings (39), potentially generating substantial
uncertainty in the resulting output.
BOX 3 | Valuing productivity gains.
The valuing productivity gains (or human capital) approach involves placing a monetary value on the estimated productivity losses associated with a disease that
are averted due to a health intervention. However, this is associated with several challenges (note that these also apply when including productivity gains within
cost-effectiveness/cost-utility analyses):
• Quantifying productivity losses or gains accurately is difficult and identifying the appropriate unit to measure is challenging. The approaches used for this can give
very different outcomes (Figure 5). For example, within the human capital approach, all potential production not performed by a person because of morbidity or
early mortality is counted as a production loss (41, 46, 47). In contrast, within the friction cost approach, the calculated production losses are limited to the time
needed to replace an ill employee and train a new employee (friction period) i.e. only the productivity lost by an ill employee before they are replaced (41, 46, 47).
• In addition to how the productivity losses are quantified, how they are valued is also variable (48). For example, whether/how to include taxes, employer-paid
benefits, how to capture labour market constraints on how much work an individual does and whether to adjust for future increases in wages are issues subject
to debate (48). This variation in how the productivity costs are quantified and valued leads to inconsistencies between studies (49).
• Valuing productivity gains can discriminate against those who receive lower wages and those not in the workforce (such as children and the elderly). This is made
worse by the fact that the productivity losses/gains related to unpaid work (such as housework and voluntary work) are difficult to quantify and are often ignored
(50).
• This approach has been criticised for not being consistent with the theoretical foundations of cost-benefit analyses in welfare economics, as it focuses on changes
in productivity rather than measuring overall social welfare and is not based on an individual’s personal valuation of the benefits (31, 51, 52).
Difficulties Capturing Non-fatal Health Outcomes
Willingness to pay estimates are less common for non-fatal health
outcomes, particularly within LMICs. Hence, many studies in
this area use averted cost or averted cost-of-illness estimates as
a proxy to quantify the monetary benefits of non-fatal health
outcomes of health interventions (33) (i.e., they look at the
averted direct costs and productivity costs that are associated with
a condition or treatment). However, the quality of such cost/cost
of illness studies is variable (54, 55). This makes it harder to
apply a cost-benefit analysis for evaluating interventions whose
main health benefits are not related to averted excess mortality.
In addition, although this is a pragmatic solution to limited data,
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it could be argued that it does not fit within cost-benefit analyses
welfarist approach underpinning.
Another method is to use a willingness to pay threshold to
convert DALYs averted or QALYs gained into a monetary value
(33). Although this is increasingly being used, it has been argued
that these conversions have no theoretical basis and can be very
arbitrary (39).
Potential Misinterpretation and Difficulties Regarding
the Practical Interpretation
The results of these studies can have the potential to be
misinterpreted. Specifically, these types of studies are typically
estimating measures of social welfare or potential economic
benefits (not estimating realisable financial benefits). This
means that the economic benefits being reported are typically
an approximation as they are a way of summarising the
health benefits experienced by a population in monetary terms
(which can be based on the approximated monetary value of
estimated productivity gains or willingness to pay methods).
For example, the human capital approach would be valuing
potential productivity gains and not the productivity gains
actually experienced by the population and the willingness to pay
technique would be valuing the benefits based on the individuals’
preferences and howmuch they would be willing to pay to obtain
the health gains. The risk here is that many stakeholders may
not realise how intangible these estimated economic benefits can
be and may misinterpret them as the actual monetary benefit to
society (i.e., real or realisable monetary benefits). For example,
if the estimated benefit-cost ratio of an intervention is 6.0, this
can be misinterpreted as the intervention generating six times the
amount spent on it (in the same way as a financial investment
portfolio might be interpreted). However, not all the estimated
economic benefits are realisable, so it may not generate cost
savings at all. This is not to say that cost-benefit analysis is not
meaningful but greater care is needed in how these studies are
reported and interpreted. Importantly, the goal of such analyses
is typically to determine if an intervention is justified in terms
of increasing societal welfare and if the estimated economic
benefits outweigh the cost of the intervention, not if it generates
fiscal cost-savings.
Similarly, when a study reports that the economic benefits
outweigh the costs of an intervention it can be referred to
as having a positive return on investment. However, this
may be misleading to policymakers as the reported return on
investment of public health interventions is increasingly being
misunderstood as a synonym for interventions generating “cost-
savings” (39). For example, a systematic review reported that the
median return on investment for public health interventions was
14.3 to 1 (56). Many misinterpreted this to mean that for every
£1 spent, public health interventions will save the public sector
£14.30 in cash; implying a cash return of 1,430% (39). However,
this is not the correct interpretation as not all of the economic
benefits calculated will be fiscal cost-savings (39).
A further limitation is that there is no threshold (marker or
cut off point for when the perceived costs outweigh the perceived
benefits) for which an intervention is considered to be of good
value in a particular setting. The decision rule of whether to
implement the intervention under consideration is based on
whether the benefits outweigh the costs (i.e., if the benefit-
cost ratio is above one) (20). Typically, cost-benefit analyses do
not account for issues surrounding fixed budget constraints for
particular sectors (e.g., health) and therefore fail to accurately
reflect the opportunity costs of additional costs being imposed
on these budgets and what other health interventions may need
to be displaced (20).
Equity and Distributional Concerns
Cost-benefit analyses involve placing an economic value on
averted mortality and morbidity. However, this can have implicit
equity and distributional concerns and many have argued that
such evaluations will intrinsically favour health interventions
benefiting richer over poorer populations (40, 41, 57). For
example, when aiming to quantify the economic benefits
experienced by a group of patients, all things being equal, the
value of the increased social welfare or productivity gains of
averting disease in richer populations will be higher than poorer
populations within the same country/setting (58, 59). In addition,
the economic benefits of treating women for a condition (who
have a higher burden of unpaid work and on average lower
salaries) could easily be estimated to be lower than for treating
men, implicitly implying that interventions targeting diseases in
men have a higher value than for women (58, 59). A way around
this issue is to assume the same value of time or life for everyone
(regardless of gender, social-economic status, and employment).
However, it could be argued that doing this means the estimated
economic benefits are more hypothetical and have a less obvious
meaning i.e. if you use the same value of time for everyone,
what do the estimated economic benefits actually correspond
to. Again, the problem is that it is not necessarily always being
understood that the economic benefits being presented are
often an approximation/theoretical and not necessarily directly
realisable to the setting’s society/economy.
It should be noted that attempts have beenmade to adapt cost-
benefit analyses to address these equity and distributional issues
(33, 34, 60). However, it is yet to been seen if these will become




Cost-effectiveness/cost-utility analyses are some of the main
types of economic evaluations used for healthcare (11). They
are a comparative analysis of the relative costs and outcomes
of two or more alternative courses of action. Cost-effectiveness
analyses measure the health consequences of an intervention in
a single natural unit (such as cases averted, or life-years saved).
However, a limitation of this is that it is difficult to compare
studies investigating interventions targeting different diseases
or different stages of care, since their health consequences will
be expressed in different units, limiting its potential use for
informing policymakers. To address, this a specific form of
cost-effectiveness known as cost-utility analysis was developed.
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Cost-utility analyses measure the health consequences with a
generic measure of health status, which can account for benefits
on both reduced morbidity and mortality, such as DALYs and
QALYs (61). As these metrics can be used for a wide range of
diseases, the cost-effectiveness estimates for different healthcare
interventions can be directly compared to each other (such
as comparing the cost-effectiveness of a malaria intervention
to a tuberculosis intervention). In practise, there has been a
blurring of the distinctions between cost-effectiveness and cost-
utility analyses; as a result, literature on cost-effectiveness often
encompasses both these approaches and cost-utility analyses
are often referred to as a cost-effectiveness analysis (16). Cost-
effectiveness/cost-utility analyses are typically based on the extra-
welfarist approach (Box 1), where the objective is traditionally to
maximise contributions to societal health, measured as the sum
of individual health status.
Figure 3 provides a visual representation of what can happen
when comparing a new health intervention to a comparator
within a cost-effectiveness/cost-utility analysis [outlined further
in (62)]. When the analysis is using a generic measure of health
status (such as DALYs/QALYs within cost-utility analyses),
standardised cost-effectiveness thresholds (an explicit cost per
unit of outcome below which an intervention is considered
cost-effective—such as £20,000 per QALY gained) are frequently
used as a decision rule to class whether an intervention is cost-
effective or not (Figure 3). Such thresholds can be determined
using a variety of methods (63). When this is done, the analysis
can consider the allocative efficiency of resources within the
healthcare sector (Table 2) (i.e., the allocation of healthcare
resources in a way that results in the maximum health gain for
a given level of expenditure) (16, 53). As such, when looking at
mutually exclusive policy options (such as different treatment
options for tuberculosis), the analysis considers the options
incrementally and identifies the most effective option that is
below the settings cost-effectiveness threshold (which is not
necessarily the same as the option that has the lowest cost per
unit of effect). In contrast, when a cost-effectiveness analysis
uses a disease or programme specific outcome measure (such as
cases averted), it is rare to have a standardised cost-effectiveness
threshold available to compare the results to and it is difficult
to compare the results to other studies. In this case, the goal of
the analysis is often to identify the most efficient option in terms
of the lowest cost per unit of effect i.e., identify the option with
the lowest cost-effectiveness ratio (such as the lowest cost per
case averted). In this context, cost-effectiveness analyses using
disease or programme specific metrics are often only concerned
with how to use healthcare resources in a way that maximises
their output for the cost (known as technical efficiency (Table 2)
(16, 53).
The outputs of cost-effectiveness/cost-utility analyses are
typically expressed in ratios (a cost per unit of effect). It is
also possible to express the outputs of cost-utility analyses
in monetary terms (such as net monetary benefit) (20, 64).
With net monetary benefit, the health outcomes are monetised
based on a cost-effectiveness threshold which represents a
societal valuation of a health metric, rather than an individuals’
willingness to pay for health gains. Hence, although this
is similar to a cost-benefit analysis, it does not have the
welfarist foundation and uses a different discussion rule
(Box 1).
Note that there are other specific forms of cost-
effectiveness analysis used for priority setting, such as
distributional cost-effectiveness analysis and extended cost-




Focus on Societal Valuation of Health
The framework behind cost-effectiveness/cost-utility analyses is
the most appropriate if you accept that health is a fundamental
good whose value should be determined by society, regardless
of how much individuals are willing to exchange for it (i.e.,
regardless of their willingness to pay). This is more consistent
with the theory of health rights that World Health Organisation
(WHO) advocates for (68). In addition, it avoids the difficulties
in valuing social welfare that occur due to market failure in the
health care market.
More Commonly Performed
Cost-effectiveness/cost-utility analyses are a more commonly
conducted and published method compared to cost-benefit
analyses (11). This makes it easier for policymakers to compare
different studies and interventions, facilitating the decision-
making process. However, the comparability of cost-effectiveness
analyses using disease or intervention specific metrics is
difficult between different health programmes/interventions and
it cannot be used to compare programmes with different
aims/outcomes; which is why cost-utility analysis was developed.
Forgoing the Need to Monetize Health Benefits
The framework does not require assigning a monetary value on
health gains. By foregoing this step, the analysis draws attention
exclusively to health benefits and avoids the corresponding
ethical and equity issues that can arise when monetizing
them (69). However, it could be argued that some of these
ethical and equity issues still arise when setting the cost-
effectiveness threshold.
Guidelines for Reporting and Methodology
There are more established guidelines/reference cases for
conducting and reporting the results of cost-effectiveness/cost-
utility analyses within the health sector and in some settings,
country-specific guidelines have been established (70–73).
Although we would argue that the methodology used is more
standardised compared to that of cost-benefit analyses (51),
it should be noted that methodological variation still occurs
between different cost-effectiveness/cost-utility analyses (such as
the costs that are included, the perspective, and the assumed
discount rate) (74, 75), particularly for settings that do not have
standardised guidelines/reference cases.
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FIGURE 3 | A schematic of the cost-effectiveness plane. Panel A indicates the four different quadrants. Panel B illustrates the different decision rules in relation to a
cost-effectiveness threshold within the different quadrants.
Cost-Effectiveness and Cost-Utility
Analyses: Limitations and Areas of Debate
Availability of Cost-Effectiveness Thresholds
A cost-effectiveness threshold is often used as a decision rule
to class whether an intervention is cost-effective or not. Some
countries have established their own cost-effectiveness thresholds
(89, 90) but this is rarer for low and lower-middle-income
countries. The absence of an established threshold can make the
results of cost-effectiveness/cost-utility analyses more difficult to
interpret. In the past, when no country-specific threshold has
been set many used the cost-effectiveness thresholds set by the
Commission on Macroeconomics and Health (91); namely a cost
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BOX 4 | Limitations of DALYs and QALYs.
DALYs: The universal disability weights used within DALY calculations do not account for how the local context may influence the burden of a disease (such as the
impact of living in poverty) (76, 77). Within the updated global burden of disease study (GBD) framework (post-GBD 2010), the disability weights are intended to solely
be measures of losses of “optimal health” and are not intended to represent losses of well-being/welfare (78, 79). Consequently, the DALY disability weights do not
consistently/fully account for the psycho-social implications of a disease or its sequelae (80) and its overall impact on quality of life. Critics have argued that disease
burden should be quantified in terms of overall welfare loss and that only measuring burden as “lost health” may lead to biases when estimating the disability weights
(78, 81, 82). Additionally, although the disability weights are meant to be standardised for a given disease, there is still variation in what weights are used in practise
(27, 83). Furthermore, in comparison to preference-based health-related quality of life measures, DALYs may not fully capture the relative benefits of interventions
that reduce the functional burden of a condition without curing it.
QALYs: QALY weights are typically estimated for a particular setting. A variety of tools/questionnaires can be used for this (84) (such as the EQ-5D questionnaire);
however, it has been shown that the different utility measurement tools provide variable results (85) and the outcomes are sensitive to the survey design and sample
(86). This can lead to variation in the utility weights being used by different studies. The generic instruments used to generate QALY utility weights are also insensitive
to some medical conditions (84) and have also been critiqued for having insufficient sensitivity to measure small but clinically meaningful changes in health status
(86). There is also ongoing debate regarding who should value the health states (patients with the condition or the general population) (84, 87), and this variation in
methodology can lead to inconsistencies in how QALY utility weights are estimated. In addition, the financial barriers for accessing QALY weight estimation tools and
databases disproportionately affect low- and middle-income countries (LMICs) (88).
FIGURE 4 | Schematic surrounding the inclusion of productivity costs within cost-effectiveness ratios. Adapted from (49).
per DALY averted< 3 and< 1 times the country’s gross domestic
product (GDP) per capita for a intervention being cost-effective
and highly cost-effective, respectively. However, these are now
considered to be too high and have become widely criticised
(63, 92–95). The WHO has outlined that these thresholds were
not intended for individual investment decisions but as a broad
principle for global/regional level analyses (96). They have argued
that these thresholds have therefore not been used in the way they
were originally intended (96). However, unfortunately, these 1-
3 times GDP per capita thresholds are currently still being used
within global health (95). Although guidance exists, determining
a country’s cost-effectiveness threshold remains a complex area
(93, 97, 98).
Depending on how it is calculated, the cost-effectiveness
threshold can be a way of capturing how much health is expected
to be foregone if the resources in question are used for an
intervention (the health opportunity cost). When this is the case,
the cost-effectiveness/cost-utility analysis can account for the
budget constraints within the healthcare sector (99). However,
in practise, the cost-effectiveness thresholds commonly used in
LMICs do not account for this and are often only an expression
of value by a specific party (such as an international organisation
or government), without consideration of health care system
constraints (99) (such as the 1 and 3 times GDP per capita
thresholds previously mentioned). Revill et al. (99) discuss these
concepts further in the context of priority setting in global health.
The Generic Measures of Health Status (DALYs and
QALYs) Have Limitations
The use of DALYs or QALYs as outcomes within cost-utility
analyses has been a notable improvement compared to only
measuring the intervention’s effect in terms of disease cases
or deaths averted, and these measures permit comparison
across different diseases or interventions. However, these generic
measures of health status have limitations (Box 4). A general
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FIGURE 5 | A hypothetical example showing the potential difference between the human capital approach or the friction cost approach when estimating productivity
costs. Costs are being discounted at 3% per year.
BOX 5 | Key messages
• In the context of resource allocation within the healthcare sector, it is important that full economic evaluations are used (which explicitly compare the costs and
consequences of the interventions or health policies in question with a comparator scenario).
• Moving forward there needs to be greater awareness within the global health field of the foundations, advantages and limitations of the different types of economic
evaluations used for informing resource allocation decisions (Table 3).
• Cost-effectiveness/cost-utility analyses have key advantages for directly comparing different health interventions when considering resource allocation within the
healthcare sector. However, it is important to acknowledge that notable non-health benefits of interventions may not be captured and it is also difficult to compare
the results of cost-effectiveness/cost-utility analyses to other sectors, limiting cross-sector comparisons.
• Cost-benefit analyses facilitate cross-sectoral comparisons and can include a wider range of benefits. However, there needs to be greater awareness of the
current methods and variations in the approaches being used when placing a monetary value on health benefits (Boxes 2, 3), and the potential for the results to
be misinterpreted.
• Importantly, the economic benefits being reported within such studies are typically an approximation - they are a way of summarising the health benefits experienced
by a population monetarily in terms of social welfare or potential economic benefits related to productivity gains. These estimated economic benefits should not
be misinterpreted as actual realisable or fiscal monetary benefits to payers or to society.
limitation of these generic summary measures is that they could
be argued to be overly simplistic and reductionist and may not
be capturing all of the health benefits of an intervention (80, 84).
In addition, these metrics do not work well in certain situations,
such as when health outcome metrics are not the most suitable.
For example, DALY/QALY metrics could be argued to fail to
account for the complexities of investigating the benefits of
prenatal genetic screening and pregnancy termination for Down’s
syndrome (such as the impact on caregivers) (19).
Often Do Not Capture Non-health Benefits and
Limited Cross-Sector Comparisons
The effectiveness framework of cost-effectiveness/cost-utility
analyses focuses on measuring the benefits of public health
interventions in terms of health gains (69, 100). When an
intervention leads to cost-offsets/health savings (such as averted
future medical costs), these cost-savings can be included and
are subtracted from the cost of the intervention. However,
many health interventions generate important additional benefits
to other sectors, such as the environment or education (69,
100). Although all financial and some non-financial broader
benefits can, in principle, be monetised and included in cost-
effectiveness/cost-utility analyses when using a broad societal
perspective, there is variation in when and how they are
included (101). Consequently, many cost-effectiveness/cost-
utility analyses only consider the benefits to the health sector
and the impacts of public health interventions on other sectors
are often not included (100). In some cases, this restrictive
perspective is linked to the mandate for the healthcare budget,
such as for solely improving health. Not capturing these non-
health benefits could be undervaluing the broader benefits of
many health interventions (39).
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TABLE 3 | Summary.
Cost-benefit analysis Cost-effectiveness/cost-utility analysis
Summary A comparative analysis of two or more alternatives in terms of their
relative costs and consequences. Within a cost-benefit analysis,
both the costs and outcomes are expressed in monetary terms.
This type of analysis typically involves summing the values of an
intervention’s costs and benefits based on the preferences of
those affected. The analysis foundation is based on the welfarist
approach (Box 1).
A comparative analysis of two or more alternatives in terms of their
relative costs and consequences. Within a cost-effectiveness
analysis, the health consequences of a health intervention are
measured in a single natural unit. In contrast, a cost-utility analysis
is a specific form of cost-effectiveness analysis, where the health
consequences are measured using a generic measure of health
status that considers both the effect on mortality and morbidity
(such as DALYs/QALYs). The analysis foundation is based on the
extra-welfarist approach (Box 1).
Advantages More consistent with how other public interventions are evaluated
and the facilitation of cross-sector comparisons (i.e., can compare
the economic benefit to investments outside of the healthcare
sector). It can therefore consider allocative efficiency of resource
allocation across different sectors/society (Table 2).
Potential to value a wider range of benefits.
A monetary output is desirable to a range of stakeholders.
More commonly performed-making comparisons of different
studies easier.
More established guidelines for methodology and reporting.
Forgoes the need to monetize health benefits and the
corresponding equity and ethical issues.
The cost-effectiveness thresholda can be a way of capturing how
much health is expected to be foregone if the resources in
question are used for an intervention accounting for the budget
constraints within the healthcare sector.
Limitations and areas of
debate
Methodological and data difficulties regarding placing a monetary
value on health benefits – particularly to non-fatal health outcomes.
Methods used are more variable and there are less
well-established reporting guidelines – making it harder to
compare studies.
Output can easily be misinterpreted and difficulties regarding
practical interpretation.
Less commonly performed than
cost-effectiveness/cost-utility analysis.
Placing a monetary value on health benefits generates notable
equity concerns.
Typically, do not account for issues surrounding fixed budget
constraints and therefore fail to accurately reflect what other health
interventions may need to be displaced.
Limited availability of cost-effectiveness thresholds.
DALY and QALY generic summary measures have limitations.
Non-health benefits may not be fully captured and there is variation
regarding if/how they are quantified and included.
Difficult to compare the results to investments outside of the
healthcare sector (limited potential for cross-sector comparisons).
They have a more limited potential in how they can consider the
allocative efficiency of resource allocation particularly beyond the
healthcare sector (Table 2).
Although cost-effectiveness/cost-utility analyses avoid the need to




Cost-benefit analyses facilitate cross-sectoral comparisons and
can include a wider range of benefits. However, there needs to be
greater awareness of the current methods and variations in the
approaches being used when placing a monetary value on health
benefits (Boxes 2, 3), and the potential for the results to be
misinterpreted. Importantly, the economic benefits being reported
within such studies are typically an approximation, in terms of
social welfare or potential economic benefits related to productivity
gains. The risk here is that many may not realise how intangible
these estimated economic benefits can be and may misinterpret
them as the actual realisable or fiscal monetary benefits.
Cost-effectiveness/cost-utility analyses have key advantages for
directly comparing different health interventions when considering
resource allocation within the healthcare sector. However, it is
important to acknowledge that notable non-health benefits of
interventions may not be captured. Although some of these
broader benefits can, in principle, be monetised and included in
analyses when using a broad societal perspective, there is
variation in when and how they are included. It is also more difficult
to compare the results of cost-effectiveness/cost-utility analyses
to investment in other sectors, limiting cross-sector comparisons.
aDepending on how it is calculated.
This limitation is particularly relevant for the evaluation
of complex interventions (such as those involving interlinked
packages of care) as the complexity means the intervention may
not fit into one of the current appraisal systems, and maximising
health may not be the intervention’s only objective (102).
Notably, the decision in question may not only involve the
health sector and can involve trade-offs between health and
other sectors/societal aims. Using non-monetary metrics limits
potential cross-sector comparisons, that is, it is hard to directly
compare the estimated value of investing in a health intervention
(based on the cost per DALY averted or QALY gained) to
investing outside of the health sector, such as in education.
This makes it difficult to use this type of analysis to justify the
reallocation of other government spending to the health sector
(such as adjusting tax policies) and more difficult for decision-
makers to compare the value of money for a broad range of
potential activities, including those from non-health sectors.
Generally, cost-effectiveness/cost-utility analyses have a more
limited potential in how they can consider the efficiency and
resource allocation compared to cost-benefit analyses (Table 2).
There is increasing recognition that the maximisation
of health gains is not the only factor that individuals
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are concerned about in relation to healthcare decision
making, as DALYs/QALYs may not be capturing the full
consequences of interest when evaluating different interventions
(24). Consequently, the importance of reporting other
metrics/outcomes as well as DALYs/QALYs is becoming
recognised (24, 29).
Variation in the Inclusion of Productivity Costs and
Potential Double-Counting of Effects
There is variation regarding what types of productivity costs are
included within cost-effectiveness ratio calculations (Figure 4).
While including the productivity costs that are related to
the patients’ productivity losses associated with accessing an
intervention is relatively uncontroversial when using a societal
perspective, many have argued that those related to the
productivity gains associated with preventedmorbidity/mortality
should not be included (10, 46, 103–107) (Figure 4). This is
because these benefits are arguably being captured within the
QALY/DALY effectiveness measure. Therefore, including these
productivity gains within the cost part of the equation would
potentially lead to the double-counting of the effectiveness
of the health intervention (Figure 4) (41). However, this
recommendation has been challenged with some arguing that
the QALY measure does not capture these productivity gains
(10, 103–107). Guidelines regarding the inclusion of these
productivity gains vary (72, 74).
As previously highlighted, estimates of productivity costs are
highly sensitive to the method used (48) and it is important to be
aware of the potential variation in methodology when comparing
studies (Box 3). This variation could lead to potential biases in
setting health policy and further guidance is needed.
Equity
It should be noted that although cost-effectiveness/cost-utility
analyses avoid the need to monetize health benefits, they are
still associated with equity and ethical issues (40, 58, 100, 108)
(such as those associated with the DALY/QALY metrics
and the setting of the cost-effectiveness threshold). For
example, cost-effectiveness/cost-utility analyses rarely provide
information about who gains and who loses from health
interventions (i.e., are equity neutral) and therefore do not
prioritise improving health among the poorest even though
this may be a societal objective. There have been new efforts
to incorporate equity in cost-effectiveness/cost-utility analyses
as a quantitative component which may potentially help with
partly addressing these limitations, such as the development
of distributional cost-effectiveness analysis and extended cost-
effectiveness analysis (65–67). However, this is still an area
that needs attention regarding practical implementation with
regards to informing resource allocation decisions in global
health (109, 110).
CONCLUSIONS
The choice of which type of health economic analysis to use is
a matter for the decision-maker(s) and will depend on the local
context, including the values and interests of the stakeholders,
the question being addressed, and the resources that are being
considered for reallocation (18, 111). However, in the context of
resource allocation within the healthcare sector, it is important
that full economic evaluations are used (which explicitly compare
the costs and consequences of the interventions or health
policies in question with a comparator scenario). Analyses that
do not do this, even if they are incorrectly referred to as a
full economic evaluation, may ignore comparisons to relevant
policy alternatives and can generate misleading conclusions
to policymakers.
Among the different types of full economic evaluations,
cost-effectiveness/cost-utility analyses and cost-benefit
analyses are typically used in this area. Although they
may appear similar, it is important to recognise when
interpreting these studies, that the welfarist foundation of
cost-benefit analyses and the extra-welfarist foundation of cost-
effectiveness/cost-utility analyses represent two fundamentally
different ways of evaluating and valuing the benefits of
health interventions (Box 1). There are also differences
in how they consider the efficiency of resource allocation
(Table 2).
Our key messages are summarised in Box 5 and Table 3.
Moving forward there needs to be greater awareness within the
public health field of the foundations, advantages and limitations
of the different types of economic evaluations used for informing
resource allocation decisions.
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